# Champions Oncology, Inc.: Form 10-Q for the period ended Oct 31, 2014

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2014-12-15
- Accepted by EDGAR: Dec 15, 2014, 08:33 ET
- Period: 2014-10-31
- Accession: 0001144204-14-073848
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420414073848/v395777_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420414073848/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2014-08-01 to 2014-10-31 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2014-05-01 to 2014-10-31 | $2.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2014-08-01 to 2014-10-31 | −$3.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2014-05-01 to 2014-10-31 | −$7.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2014-08-01 to 2014-10-31 | $10.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2014-05-01 to 2014-10-31 | $15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2014-08-01 to 2014-10-31 | −$3.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2014-05-01 to 2014-10-31 | −$6.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2014-08-01 to 2014-10-31 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2014-05-01 to 2014-10-31 | −$0.11 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2014-08-01 to 2014-10-31 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2014-05-01 to 2014-10-31 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2014-08-01 to 2014-10-31 | 67,855,325 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2014-05-01 to 2014-10-31 | 67,854,228 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2014-05-01 to 2014-10-31 | −$5.2m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 6 months, 2014-05-01 to 2014-10-31 | $71.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-10-31 | $575.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-10-31 | $2.1m | us-gaap:AssetsCurrent |
| Total assets | at 2014-10-31 | $3.3m | us-gaap:Assets |
| Current liabilities | at 2014-10-31 | $3.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-10-31 | $5.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2014-10-31 | −$1.9m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/771856/000114420414073848/v395777_10q.htm

Filed Dec 15, 2014.
Source: SEC EDGAR, the filing index for accession 0001144204-14-073848. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
